Altavant Sciences to Provide Clinical Update at 2019 Respiratory Innovation Summit

« Back

Cary, N.C. and BASEL, Switzerland — May 9, 2019 — Altavant Sciences, a company in the Roivant family focused on clinical development of novel therapies for pulmonary arterial hypertension (PAH) and other indications, today announced that it has been invited to present at the 2019 Respiratory Innovation Summit (RIS) being held May 17 in Dallas, TX. Altavant’s Chief Operating Officer, Lyn Baranowski, will present an overview of the company and its lead tryptophan hydroxylase (TPH) inhibitor, which is preparing to enter Phase 2 development for the treatment of pulmonary arterial hypertension (PAH) later this quarter. The presentation will take place during the Morning Showcase beginning at 8:45am CT.

Commenting on the presentation, Ms. Baranowski stated, “RIS is an excellent venue to continue raising visibility of Altavant and our clinical programs to an audience of respiratory experts. In addition, it provides us with an opportunity to advance the company’s strategic goals, which include bolstering our development pipeline with additional rare respiratory disease candidates.”

The Respiratory Innovation Summit is an annual one-day event where entrepreneurs, thought leaders, investors and corporations will share ideas and present advances in therapeutics, diagnostics, smart tools and devices for the treatment of pulmonary diseases.

*name applied for; application pending

About Altavant Sciences
Altavant Sciences is a wholly owned biopharmaceutical subsidiary of Roivant Sciences. The company, formed in 2018, is focused on elevating patient-centric drug development in rare respiratory diseases with an initial focus on pulmonary arterial hypertension. Altavant leverages the Roivant platform to develop therapies that address high unmet medical needs while driving greater efficiency in research, clinical development and commercialization. Altavant’s lead candidate is rodatristat ethyl*, a tryptophan hydroxylase (TPH) inhibitor that reduces the body’s peripheral production of serotonin, thereby lowering circulating serotonin levels in diseases where excessive production of the hormone has been implicated in pathogenesis – including pulmonary arterial hypertension, certain types of cancer, GI disorders, fibrosis and inflammation. Rodatristat ethyl is preparing to enter Phase 2 testing in patients with pulmonary arterial hypertension. Additional rare respiratory indications are being explored. For more information, please visit www.altavant.com.

About Roivant 
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. For more information, please visit www.roivant.com.